CureGene Completes First‑Participant Dose in Phase I Trial of CG‑0416, Advancing Clinical Development of Novel Oral Liver-Targeting THR-β Agonist
- Written by PR Newswire
SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- CureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β agonist developed in-house, in Australia. Subject enrollment is progressing smoothly.
CG-0416 is designed based on CureGene's proprietary prodrug platform,...
